These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 20160358)

  • 1. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
    Peroja P; Pedersen M; Mantere T; Nørgaard P; Peltonen J; Haapasaari KM; Böhm J; Jantunen E; Turpeenniemi-Hujanen T; Rapakko K; Karihtala P; Soini Y; Vasala K; Kuittinen O
    Sci Rep; 2018 Oct; 8(1):14814. PubMed ID: 30287880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive cell properties of B cells carrying the BCL2 translocation and their potential roles in the development of lymphoma of germinal center type.
    Sakai T; Nishikori M; Tashima M; Yamamoto R; Kitawaki T; Takaori-Kondo A; Suzuki T; Tsuzuki S; Uchiyama T
    Cancer Sci; 2009 Dec; 100(12):2361-7. PubMed ID: 19780757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.
    Devin J; Kassambara A; Bruyer A; Moreaux J; Bret C
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31336593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.
    Roberson PL; Smith LB; Morgan MA; Schipper MJ; Wilderman SJ; Avram AM; Kaminski MS; Dewaraja YK
    Cancer Biother Radiopharm; 2017 Nov; 32(9):309-319. PubMed ID: 29083933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin Lymphoma (NHL) in Pakistan.
    Pervez S
    Int J Mol Cell Med; 2012; 1(1):62-3. PubMed ID: 24551760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma.
    Küçükzeybek BB; Bener S; Çallı AO; Paksoy TD; Payzin B
    Turk J Haematol; 2013 Sep; 30(3):275-82. PubMed ID: 24385807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature.
    Bhagavathi S; Micale MA; Les K; Wilson JD; Wiggins ML; Fu K
    Am J Surg Pathol; 2009 Oct; 33(10):1463-9. PubMed ID: 19675454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology.
    Winter JN
    Curr Hematol Malig Rep; 2007 Oct; 2(4):235-41. PubMed ID: 20425375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.
    Pervez S; Nasir MI; Moatter T; Ahsan A; Haq A; Siddiqui T
    J Cancer Res Ther; 2009; 5(4):254-62. PubMed ID: 20160358
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.